MedPath

Cardiff Oncology

Cardiff Oncology logo
🇺🇸United States
Ownership
Public
Established
1999-01-01
Employees
31
Market Cap
-
Website
http://www.cardiffoncology.com
Introduction

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Phase 2
Active, not recruiting
Conditions
CRC
Metastatic Colorectal Cancer
KRAS/NRAS Mutation
Interventions
Drug: FOLFIRI
Drug: FOLFOX
First Posted Date
2023-10-30
Last Posted Date
2025-04-29
Lead Sponsor
Cardiff Oncology
Target Recruit Count
113
Registration Number
NCT06106308
Locations
🇺🇸

Mayo Clinic - Arizona, Phoenix, Arizona, United States

🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

St. Bernards Medical Center, Jonesboro, Arkansas, United States

and more 38 locations

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Colorectal Cancer
Interventions
First Posted Date
2022-10-25
Last Posted Date
2025-01-10
Lead Sponsor
Cardiff Oncology
Target Recruit Count
23
Registration Number
NCT05593328
Locations
🇺🇸

Mayo Clinic in Arizona - Phoenix Campus, Phoenix, Arizona, United States

🇺🇸

Central Arkansas Radiation Therapy Institute - Cancer Center, Little Rock, Arkansas, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

and more 24 locations

Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2
Completed
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2021-02-12
Last Posted Date
2025-01-07
Lead Sponsor
Cardiff Oncology
Target Recruit Count
43
Registration Number
NCT04752696
Locations
🇺🇸

Mayo Clinic Phoenix, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

🇺🇸

University of Kansas Medical Center, Westwood, Kansas, United States

and more 3 locations

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Conditions
Metastatic Colorectal Cancer
KRAS Gene Mutation
First Posted Date
2020-06-25
Last Posted Date
2024-02-12
Lead Sponsor
Cardiff Oncology
Registration Number
NCT04446793

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1
Completed
Conditions
Metastatic Colorectal Cancer
KRAS Gene Mutation
Interventions
First Posted Date
2019-02-04
Last Posted Date
2025-03-04
Lead Sponsor
Cardiff Oncology
Target Recruit Count
68
Registration Number
NCT03829410
Locations
🇺🇸

Mayo Clinic Cancer Center, Phoenix, Arizona, United States

🇺🇸

CARTI Cancer Center, Little Rock, Arkansas, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 4 locations

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2
Completed
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
First Posted Date
2018-01-29
Last Posted Date
2024-11-07
Lead Sponsor
Cardiff Oncology
Target Recruit Count
72
Registration Number
NCT03414034
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2017-10-06
Last Posted Date
2023-02-27
Lead Sponsor
Cardiff Oncology
Target Recruit Count
72
Registration Number
NCT03303339
Locations
🇺🇸

University of California Los Angeles, Los Angeles, California, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

University of Kansas Cancer Center, Westwood, Kansas, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath